tiprankstipranks
Trending News
More News >
Kangji Medical Holdings Limited (HK:9997)
:9997

Kangji Medical Holdings Limited (9997) AI Stock Analysis

Compare
3 Followers

Top Page

HK

Kangji Medical Holdings Limited

(Frankfurt:9997)

Rating:82Outperform
Price Target:
HK$9.00
▲(16.43%Upside)
Kangji Medical Holdings Limited scores highly due to its robust financial performance, characterized by strong revenue growth and profitability, financial stability, and efficient cash management. The technical analysis supports a bullish trend, further enhancing the stock's appeal. Valuation metrics such as a reasonable P/E ratio and attractive dividend yield contribute to a favorable outlook.

Kangji Medical Holdings Limited (9997) vs. iShares MSCI Hong Kong ETF (EWH)

Kangji Medical Holdings Limited Business Overview & Revenue Model

Company DescriptionKangji Medical Holdings Limited (9997) is a leading Chinese medical device company specializing in the development, manufacturing, and marketing of minimally invasive surgical instruments and accessories. The company's product portfolio includes disposable and reusable surgical instruments that cater to various medical specialties, including gynecology, urology, and general surgery. Kangji Medical is committed to enhancing surgical outcomes and patient care through innovative and high-quality medical solutions.
How the Company Makes MoneyKangji Medical Holdings Limited generates revenue primarily through the sale of its minimally invasive surgical instruments and accessories. The company's revenue streams are largely driven by the demand for its disposable and reusable products used in surgical procedures across hospitals and healthcare facilities. Kangji Medical also benefits from strategic partnerships with medical institutions and continued investment in research and development to expand its product offerings. The company's growth is further supported by the increasing adoption of minimally invasive surgical techniques in China and other markets.

Kangji Medical Holdings Limited Financial Statement Overview

Summary
Kangji Medical Holdings Limited exhibits strong financial performance across all verticals. The income statement reveals consistent revenue and profitability growth, while the balance sheet shows financial stability with low leverage. The cash flow statement indicates robust cash generation and efficient capital management. Overall, the company is well-positioned for future growth with its solid financial foundation.
Income Statement
92
Very Positive
Kangji Medical Holdings Limited has demonstrated consistent revenue growth over the years, with a significant increase in total revenue from 2023 to 2024. The company maintains high gross profit margins, indicating strong cost control and pricing power. The net profit margin is also robust, reflecting efficient operations and profitability. EBIT and EBITDA margins are healthy, showcasing strong operational performance.
Balance Sheet
87
Very Positive
The balance sheet is strong, with a low debt-to-equity ratio due to minimal total debt, indicating low financial risk. The company has a high equity ratio, signifying a substantial equity base relative to total assets. Return on equity is impressive, suggesting effective use of shareholders' funds to generate profits. Overall, the balance sheet reflects financial stability and conservative leverage.
Cash Flow
89
Very Positive
The cash flow statement shows substantial operating cash flow, comfortably covering net income, highlighting strong cash generation. Free cash flow has grown significantly, pointing to effective capital expenditure management. The company's ability to maintain positive free cash flow alongside growth indicates a solid cash position and investment capacity.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
1.01B926.02M786.37M690.26M511.49M
Gross Profit
797.65M741.20M635.25M562.93M431.47M
EBIT
592.69M442.47M446.02M417.74M311.67M
EBITDA
562.61M464.58M586.65M427.25M319.14M
Net Income Common Stockholders
581.44M504.02M478.74M456.79M250.30M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.24B2.69B2.83B3.01B2.78B
Total Assets
2.92B4.26B3.98B3.39B3.02B
Total Debt
3.52M43.99M49.02M4.05M5.05M
Net Debt
-1.12B-2.63B-2.77B-2.95B-2.23B
Total Liabilities
289.39M319.97M266.10M129.94M83.65M
Stockholders Equity
2.63B3.65B3.37B3.26B2.94B
Cash FlowFree Cash Flow
504.52M331.70M243.62M404.88M203.21M
Operating Cash Flow
560.10M419.62M319.31M435.75M221.04M
Investing Cash Flow
1.04B-391.70M-369.98M-160.09M-610.98M
Financing Cash Flow
-1.70B-243.53M-472.79M-97.61M2.15B

Kangji Medical Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.73
Price Trends
50DMA
7.29
Positive
100DMA
6.98
Positive
200DMA
6.36
Positive
Market Momentum
MACD
0.12
Positive
RSI
53.39
Neutral
STOCH
68.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9997, the sentiment is Positive. The current price of 7.73 is above the 20-day moving average (MA) of 7.72, above the 50-day MA of 7.29, and above the 200-day MA of 6.36, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 68.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9997.

Kangji Medical Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
€9.37B14.4218.36%3.78%7.13%13.39%
81
Outperform
€1.64B10.673.72%8.36%11.84%-2.22%
77
Outperform
$27.90B12.278.95%4.36%-3.09%0.67%
66
Neutral
HK$4.51B20.1611.24%1.18%11.23%20.39%
54
Neutral
$5.38B3.27-45.10%3.30%16.81%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:9997
Kangji Medical Holdings Limited
7.73
2.07
36.52%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
25.50
-1.75
-6.42%
HK:1066
Shandong Weigao Group Medical Polymer Co
6.06
1.81
42.52%
HK:1358
PW Medtech Group Ltd.
1.13
0.15
15.66%

Kangji Medical Holdings Limited Corporate Events

Kangji Medical Announces Board Composition and Roles
May 23, 2025

Kangji Medical Holdings Limited has announced the composition of its Board of Directors, detailing the roles and functions of each member. This announcement highlights the company’s governance structure, which includes a mix of executive, non-executive, and independent non-executive directors, potentially impacting its strategic direction and stakeholder confidence.

Kangji Medical Approves Key Resolutions at AGM
May 23, 2025

Kangji Medical Holdings Limited announced the results of its Annual General Meeting held on May 23, 2025. All proposed resolutions, including the approval of financial statements, declaration of dividends, re-election of directors, and granting of mandates for share issuance and buyback, were passed with significant majorities. These resolutions reflect the company’s stable governance and strategic direction, potentially impacting its market operations and shareholder value positively.

Kangji Medical Offers Currency Choice for 2024 Final Dividend
May 23, 2025

Kangji Medical Holdings Limited has announced the election of currency options for its final dividend payment for the year ended December 31, 2024. Shareholders can choose to receive the dividend in either Renminbi or Hong Kong Dollars, providing flexibility in currency preference. This decision reflects the company’s commitment to accommodating shareholder needs and could potentially enhance shareholder satisfaction by offering a choice in dividend currency. The final dividend is set at RMB 24 cents per share, with an equivalent of HKD 26.13 cents per share, based on the exchange rate published by the People’s Bank of China.

Kangji Medical Announces Final Dividend Payment Details for 2024
May 23, 2025

Kangji Medical Holdings Limited has announced an update regarding the payment of its final dividend for the year ended December 31, 2024. Shareholders will receive a dividend of RMB 0.24 per share, with an option to receive the payment in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.08875. The payment date is set for July 16, 2025, with the closing date for currency option election on June 23, 2025. This announcement reflects the company’s commitment to providing returns to its shareholders and may influence investor sentiment positively.

Kangji Medical Updates Nomination Committee to Enhance Governance
May 23, 2025

Kangji Medical Holdings Limited announced changes to its Nomination Committee, effective May 23, 2025. Ms. Shentu Yinguang has been appointed as a member, while Mr. Zhong Ming has stepped down as chairman and member, and Mr. Jiang Feng has been appointed as the new chairman. These changes align with amendments to the Hong Kong Stock Exchange’s Listing Rules and Corporate Governance Code, aiming to improve board effectiveness and diversity, thereby enhancing the company’s corporate governance practices.

Kangji Medical Terminates Subsidiary Disposal, Secures Land Resumption Deal
May 13, 2025

Kangji Medical Holdings Limited announced the termination of a discloseable transaction involving the disposal of a subsidiary due to the purchaser’s inability to fulfill payment obligations. The termination agreement allows Kangji to retain RMB46 million and includes provisions for the return of company records and land resumption. Additionally, Kangji entered a land resumption agreement with a PRC government authority, resulting in a compensation of approximately RMB29.3 million. The company expects to realize a gain of RMB39.3 million from these agreements, impacting its financial position positively.

Kangji Medical Holdings Schedules 2025 Annual General Meeting
Apr 25, 2025

Kangji Medical Holdings Limited has announced its upcoming annual general meeting scheduled for May 23, 2025, in Hong Kong. Key agenda items include the approval of audited financial statements for 2024, a final dividend declaration of RMB24 cents per share, re-election of independent non-executive directors, and re-appointment of Ernst & Young as auditors. The meeting will also address resolutions concerning the issuance and management of company shares, indicating a strategic focus on financial stability and governance.

Kangji Medical’s Associate Gains Approval for Innovative Surgical Robot
Apr 22, 2025

Kangji Medical Holdings Limited announced that its associate, Hangzhou Weijing Medical Robot Co., Ltd., has received regulatory approval from China’s National Medical Products Administration for its four-arm laparoscopic surgical robot. This approval marks a significant milestone in Weijing Medical’s commercialization efforts and strengthens Kangji Medical’s strategic position in the minimally invasive surgery market. The company plans to leverage its sales, distribution, and manufacturing capabilities to support the development and commercialization of Weijing Medical’s surgical robotic systems.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.